Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin
Autore:
Grundmann, JU; Bockelmann, R; Bonnekoh, B; Gollnick, HPM;
Indirizzi:
Otto Von Guericke Univ, Dept Dermatol & Venereol, D-39120 Magdeburg, Germany Otto Von Guericke Univ Magdeburg Germany D-39120 9120 Magdeburg, Germany
Titolo Testata:
PHOTOCHEMISTRY AND PHOTOBIOLOGY
fascicolo: 4, volume: 74, anno: 2001,
pagine: 587 - 592
SICI:
0031-8655(200110)74:4<587:UERCOM>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
DUAL 5-LIPOXYGENASE/CYCLOOXYGENASE INHIBITOR; CUTANEOUS MALIGNANT-MELANOMA; ULTRAVIOLET-RADIATION; TOPICAL INDOMETHACIN; BETA-CAROTENE; SKIN-CANCER; MODEL; SUNBURN; DRUGS; INFLAMMATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Grundmann, JU Otto Von Guericke Univ, Dept Dermatol & Venereol, Leipziger Str 44, D-39120 Magdeburg, Germany Otto Von Guericke Univ Leipziger Str 44 Magdeburg Germany D-39120
Citazione:
J.U. Grundmann et al., "UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin", PHOTOCHEM P, 74(4), 2001, pp. 587-592

Abstract

UV light exerts hazardous effects such as induction of skin cancer and premature skin aging. In this study we evaluated an assumptive anti-inflammatory effect of the nonsedative histamine H1-receptor antagonist, mizolastine,on UV-induced acute sunburn reaction. Therefore, a clinical, randomized, double-blind, four-arm, crossover study was conducted in healthy young female volunteers (skin type II) comparing the UV sensitivity under mizolastine,acetyl-salicylic acid (ASA), indomethacin or a mizolastine/ASA combination. Moreover, HaCaT keratinocytes were incubated with mizolastine under various UV treatment modalities in vitro to study its effect on the release of inflammatory cytokines, i.e. interleukin (IL)-1 alpha, IL-6 and tumor necrosis factor alpha, (TNF-alpha). All three drugs were effective in suppressingthe UVB-, UVA- and combined UVA/UVB-erythema. However, the strongest effects were observed using the combined treatment with both 250 mg ASA and 10 mg mizolastine. An inhibitory effect in vitro of 10 nM mizolastine upon UV-induced cytokine release from HaCaT keratinocytes was observed for IL-1 alpha at 24 h after 10 J/cm(2) UVA1, for IL-6 at 48 h after 10 J/cm(2) UVA1 and30 mJ/cm(2) UVB, and also for TNT-alpha at 4 h after 10 J/cm(2) UVA, 10 J/cm(2) UVA1 and 30 mJ/cm(2) UVB, respectively. The combination of mizolastine and ASA can be strongly recommended as a protective measure against UV erythema development with a lower unwanted side effect profile than that of the hitherto treatment modality, i.e. indomethacin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 15:31:19